[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053518":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":72,"whyStopped":11,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intradermal Hyaluronidase","EXPERIMENTAL",null,[13],"Drug: Hyaluronidase (Hylenex)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Hyaluronidase (Hylenex)","Patients will receive monthly injections of hyaluronidase into 1 finger on each hand over a 28 week treatment period.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Kimberly Hashemi, MD","CONTACT","943-792-9784","bowerman@musc.edu",[27],{"facility":5,"status":11,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Charleston","South Carolina","29425","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-79.93275,32.77632,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":41,"phoneExt":11,"email":25},"843-792-9784",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Kimberly Hashemi","Associate Professor","100053518","early-phase-1-hyaluronidase-for-sclerodactyly-in-systemic-sclerosis-trial-100053518",false,"NCT07697274","Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial","Digital Intradermal Hyaluronidase for Sclerodactyly in Systemic Sclerosis","HASSc","Inclusion Criteria:\n\n* Age ≥18 and \\\u003C60 years\n* Diagnosis of systemic sclerosis\n* Presence of sclerodactyly\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Known hypersensitivity to hyaluronidase\n* Pregnancy or breastfeeding\n* Unstable systemic disease\n* Recent changes in systemic immunomodulatory therapy\n* Conditions interfering with safe digital injections","ALL","18 Years","60 Years",{"count":58,"type":59},10,"ESTIMATED","INTERVENTIONAL",[62],"EARLY_PHASE1","Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease. Several studies have demonstrated that exogenous hyaluronidase is very effective at improving systemic sclerosis associated microstomia. Therefore, this study aims to explore hyaluronidase for systemic sclerosis associated sclerodactyly.",[65,66],"Systemic Sclerosis","Sclerodactyly",[68,69,70,71],"Hyaluronidase","Digital fibrosis","Hand function","Autoimmune disease","NOT_YET_RECRUITING","2026-07-08",{"date":75,"type":76},"2026-07-13","ACTUAL",{"date":78,"type":59},"2026-09-01",{"date":80,"type":59},"2027-11",{"name":5,"class":6},1]